Ebola, Meningitis, Marburg, Lassa Fever to be piloted in African Risk Capacity Outbreaks & Epidemics Insurance scheme

Tue, Apr 10, 2018 | By publisher


Health

 

The African Risk Capacity, ARC, an agency of the African Union, is developing an insurance product to facilitate rapid, first-line financial responses to disease outbreaks. In the pilot phase, Ebola, Marburg, Meningitis, and Lassa Fever will be covered. More than 30 countries across Africa are at risk of an outbreak of one or more of these four epidemic-prone diseases.

The ministries of Health in Guinea and Uganda, the two countries implementing ARC’s Outbreak and Epidemic, O&E, Pilot Programme, selected these four pathogens due to the history-based potential for outbreaks and accompanying devastating impact on populations and economies.

O&E builds on ARC’s successes in implementing climate disaster risk financing programmes in Africa. It is designed as an integrated system to enable governments to respond early and effectively to public health emergencies. The programme will work with countries to determine their epidemic risks and select pathogens to be covered, optimize early warning systems, create pre-established contingency plans for rapid response, and provide access to swift disbursement of financing through parametric insurance.

Mohamed Beavogui, director general of ARC Agency and United Nations Assistant Secretary General said, “Identifying this first set of pathogens for our programme is a significant milestone. After working closely with the governments of Uganda and Guinea, and with WHO AFRO, Africa CDC, and other stakeholders, this is a product that will make a difference for Africa, that targets the public health needs of Africans, and that was built through African and international collaboration.”

The highest global incidence of bacterial meningitis occurs in the “meningitis belt” of Africa, spanning 26 countries from Senegal to Ethiopia. West, East, and Central African nations are at risk of outbreaks of the Marburg virus disease and Lassa Fever, both of which are viral haemorrhagic fevers.

The 2015 Ebola outbreak in West Africa resulted in 11,310 deaths in Guinea, Sierra, and Liberia with an estimated economic impact on the three countries of US $2.8 billion, according to the World Bank. Studies estimate that initiating the Ebola response two months earlier could have reduced the fatalities by up to 80%.

On the need to rapidly respond to disasters on the continent, Beavogui said: “African governments identified the need for faster financing to avoid another tragedy like the recent Ebola outbreak in West Africa, and ARC is working in close collaboration with governments and our partners to address that need. We are creating an innovative system that acts early to finance efficient, effective responses to help stem an outbreak before it reaches a crisis level.”

The ARC O&E pilot programme is supported by The Rockefeller Foundation and Swiss Development Cooperation. Metabiota Inc, Health Systems Consult Limited and public health economists affiliated with Columbia University are collaborating with ARC on the development of its pilot product.

When launched as a full product in the fall of 2019 and made available to all African Union countries, O&E will help strengthen African health systems by contributing to national capacities in risk profiling and contingency/response planning, and ensuring that slow and unpredictable funding does not continue to prevent African countries and partners from adequately responding to outbreaks and epidemics.

– Apr. 10, 2018 @ 16:59 GMT |

Tags:


Gavi concludes agreements to facilitate donations of 305,000 mpox vaccine doses on behalf of US, with the first delivery to Nigeria 

A shipment of 11,200 doses, donated by the United States of America and facilitated by Gavi, the Vaccine Alliance, have...

Read More
NAFDAC busts Rice repackaging factory in Nasarawa

THE National Agency for Food and Drug Administration and Control (NAFDAC) on Thursday raided a rice-repackaging factory in New Karu,...

Read More
Manufacturer of recalled drug in custody – NAFDAC

THE manufacturer of the recalled batch of Deekins Amoxycilin 500mg capsule is in custody, says the National Agency for Food...

Read More